ELAB Nilai Total Aset Perusahaan Elevai Labs Inc

ELAB (Elevai Skincare) - tandha merek perusahaan

The price trend for the total assets of Elevai Labs Inc. (ELAB), which currently stands at 22.84, demonstrates the business development of luxury aesthetic medicine products. Elevai Labs Inc. (ELAB) relies on diverse distribution channels, including online sales and clinics, which stabilizes profitability. High physician loyalty and rapid growth in retail demand are forming a sustainable regenerative ecosystem, as the brand implements stem cell-based biotechnologies for tissue renewal.

ELAB (Elevai Labs Inc.) riwayat Total Aset Perusahaan saka 21.02.2024 nganti 30.10.2026

Rincian analitis lan laporan data perusahaan Elevai Skincare (ELAB)

- rega saham lan konsensus proyeksi valuasi:
Bagan rega elevaiskincare.com|ELAB - Bagan rega target
- data kapitalisasi pasar:
Biji pasar Elevai Corp|ELAB - Nilai Perusahaan
- statistik nilai buku emiten:
Nilai Akuntansi Saham Elevai Labs|ELAB - Kapitalisasi Buku|Rasio Kapitalisasi Pasar marang Nilai Buku elevaiskincare.com|ELAB - Aset Agregat Perusahaan
- indikator beban utang lan likuiditas:
Rasio Kabeh Utang marang Dana Pribadi Elevai Labs Inc.|ELAB - Utang jangka dawa marang ekuitas|Rasio utang jangka cendhak marang ekuitas Elevai Corp|ELAB - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku Elevai Corp|ELAB - Kewajiban jangka dawa perusahaan|Silihan lan utang jangka cendhak perusahaan Elevai Labs|Koefisien jangkoan perantara elevaiskincare.com
- indikator pendapatan resik lan kelipatan nilai:
ELAB - Bathi resik perusahaan
Pambiji fundamental:Elevai Labs Inc.
Produk sing diprodhuksi Elevai Labs Inc.

Fundamental screening of Elevai Labs Inc. (ELAB) resources is based on the aggregate of assets and liabilities, where the trend of gross assets, reverse-calculated via return on assets (ROA), demonstrates the actual scale of balance sheet expansion. The growth of this metric confirms the firm's capitalization; however, for a company in the market entry phase of exosomes, this is a critical marker of resilience against regulatory risks and premium marketing costs amid limited cash.

Pesaing wigati

KRYS (krystalbio.com) - Aset Agregat Perusahaan|Aset Agregat Perusahaan Apogee Therapeutics, Inc.|Arcutis - Nilai Total Aset Perusahaan|Total Aset Perusahaan VCEL|ORKA (Oruka Pharma) - Nilai Agregat Aset|Total Aset Perusahaan SMTI (Sanara MedTech)|Total Aset Perusahaan DBV Tech DBVT|SLSN - Aset Agregat Perusahaan|Nilai Agregat Aset DERM (Journey Medical)|Forte Biosciences, Inc (FBRX) - Aset Agregat Perusahaan|Gunggung Aset Perusahaan Empro Corporation|SLGL (Sol-Gel Technologies) - Total Aset Perusahaan|Total Aset Perusahaan Revive Pro Care|Gunggung Aset Perusahaan MDCX (Medicus Pharma)|VRCA (verrica.com) - Nilai Agregat Aset|Aset Agregat Perusahaan Hoth Therapeutics HOTH|Gunggung Aset Perusahaan Biofrontera, Inc. (BFRI)|VYNE - Aset Agregat Perusahaan|SNOA - Total Aset Perusahaan|QNRX: Total Aset Perusahaan|AZTR - Gunggung Aset Perusahaan|Aset Agregat Perusahaan Dermata|Total Aset Bisnis RVNC (Revance Therapeutics Inc)